Inferra AI / Company / BLFS
Biolife Solutions Inc.
BLFS · Health Care
Last earnings Aug 6, 2026
Key results
Total revenuequarter
$28.5 million
Total revenue of $28.5 million, up 21% over Q2 2025
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Growthquarter
up 21%
Total revenue of $28.5 million, up 21% over Q2 2025
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
GAAP gross marginquarter
64%
GAAP gross margin of 64% and non-GAAP adjusted
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
REVENUE Total revenue for the second quarter of 2026 was $28.5 million, an increase of $5.0 million, or 21%, from $23.4 million for the second quarter of 2025 and up $1.0 million, or 4%, from the first quarter of 2026.
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Gross marginquarter
64%
GROSS MARGIN Gross margin (GAAP) for the second quarter of 2026 was 64% compared with 65% for the second quarter of 2025.
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Adjusted gross marginquarter
65%
Adjusted gross margin (non-GAAP) for the second quarter of 2026 was 65% compared with 66% for the second quarter of 2025.
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Operating incomequarter
$1.7 million
OPERATING INCOME (LOSS) Operating income (GAAP) for the second quarter of 2026 was $1.7 million compared with an operating loss of $16.1 million for the second quarter of 2025.
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Adjusted operating incomequarter
$3.1 million
Adjusted operating income (non-GAAP) for the second quarter of 2026 was $3.1 million compared with an adjusted operating loss of $0.3 million for the second quarter of 2025.
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Net incomequarter
$45.1 million
NET INCOME (LOSS) Net income (GAAP) for the second quarter of 2026 was $45.1 million compared with a net loss of $15.3 million for the second quarter of 2025.
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
AI analysis
Q2 2026 · reported Aug 6, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
GAAP gross margin
Percent of revenue, as stated
EX-99 · Aug 6, 2026 Margin values as stated in the release.
Headline figures
| Metric | Q2 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Total revenue | $28.5 million | — | — |
| Growth | up 21% | — | — |
| GAAP gross margin | 64% | — | 65% |
| Gross margin | 64% | — | 65% |
| Adjusted gross margin | 65% | — | 66% |
| Operating income | $1.7 million | — | — |
| Adjusted operating income | $3.1 million | — | — |
| Net income | $45.1 million | — | — |
Guidance · company-stated
No guidance located in the held release
Margin
Capital allocation
Significant estimates and assumptions by management affect the Company s valuation of market-based stock awards, fair value of marketable debt securities, remeasurement of fair value of financial instruments utilizing the fair value option, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, net realizable value of inventory, and provision for income taxes.
2026-01, Initial Measurement of Paid-in-Kind Dividends on Equity-Classified Preferred Stock ("ASU 2026-01").
Event summary
(Nasdaq BLFS) ( BioLife or the Company ), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ( CGT ) market, announces financial results for the three and six months ended June 30, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Significant estimates and assumptions by management affect the Company s valuation of market-based stock awards, fair value of marketable debt securities, remeasurement of fair value of financial instruments utilizing the fair value option, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, net realizable value of inventory, and provision for income taxes.
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
2026-01, Initial Measurement of Paid-in-Kind Dividends on Equity-Classified Preferred Stock ("ASU 2026-01").
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
This guidance requires entities to initially measure paid-in-kind ("PIK") dividends on equity-classified preferred stock based on the dividend rate specified in the related agreement applied to the instrument s liquidation preference.
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
The amendments are intended to improve comparability by reducing diversity in practice related to the measurement of such dividends and do not affect the timing of recognition.
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
The fair value of the Company was determined by calculating the Company's market capitalization as of the disposal date plus any invested capital remaining of the Company, which included outstanding debt and financing lease liabilities, modified by an estimated market 15 Table of Contents acquisition premium.
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
Interest expenses directly associated with the debt of a disposed entity is reported in discontinued operations below.
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
Our Sexton cell processing product line includes hPL for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal cryogenic vials that are purpose-built rigid containers used in CGT that can be filled manually or with high throughput systems, CryoCase cryo-compatible transparent rigid containers designed for closed-system fill and retrieval, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination.
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
The Company, management, and the Company's board of directors (the "Board") determined the SAVSU Divestiture would enable the Company to optimize its product portfolio by focusing on its recurring higher margin revenue streams its cell processing products, in addition to the divestitures the Company executed during 2024.
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements.
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us.
SEC original ↗Biolife Solutions Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Legal Proceedings 42 Item 1A.
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks and uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods.
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
The global business environment continues to be impacted by cost pressure, volatility in global trade policies through significant increases in tariffs, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors.
SEC original ↗Biolife Solutions Inc. — 10-Q Quarterly report10-QAug 6, 2026
Earnings deck slides
0 decks with slide viewBiolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Biolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Biolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Biolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Biolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Biolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Biolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Biolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Biolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Biolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Biolife Solutions Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
35 documents- Q3 2026
- 8-KBLFS
Oct 6, 2026
- Q2 2026
- 8-KBLFS
Sep 9, 2026
- 8-KBLFS
Aug 6, 2026
- 10-QBLFS
- 8-KBLFS
Aug 3, 2026
- 8-KBLFS
Jul 22, 2026
- EX-99BLFS
Jul 22, 2026
- Q1 2026
- 8-KBLFS
Jun 3, 2026
- 8-KBLFS
May 7, 2026
- 10-QBLFS
- Q4 2025
- 8-KBLFS
Mar 2, 2026
- 8-KBLFS
Feb 26, 2026
- 10-KBLFS
Feb 26, 2026
- 8-KBLFS
Jan 12, 2026
- EX-99BLFS
Jan 12, 2026
- 8-KBLFS
Jan 9, 2026
- Q3 2025
- 8-KBLFS
Nov 17, 2025
- 8-KBLFS
Nov 6, 2025
- 10-QBLFS
- Q2 2025
- 8-KBLFS
Aug 21, 2025
- 8-KBLFS
Aug 7, 2025
- 10-QBLFS
- Q1 2025
- 8-KBLFS
May 8, 2025
- 10-QBLFS
- Q4 2024
- 8-KBLFS
Mar 24, 2025
- EX-99BLFS
Mar 24, 2025
- 8-KBLFS
Mar 3, 2025
- 10-KBLFS
Mar 3, 2025
- 8-KBLFS
Jan 13, 2025
- EX-99BLFS
Jan 13, 2025
- Q3 2024
- 8-KBLFS
Dec 20, 2024
- EX-99BLFS
Dec 20, 2024
- 8-KBLFS
Nov 20, 2024
- 8-KBLFS
Nov 12, 2024
- 10-QBLFS
Nov 12, 2024
Earnings releases
4 documentsPresentations
11 documents
Transcripts
0 documentsNo transcripts for Biolife Solutions Inc. are held in this edition of the library.
Mentioned by
2 companiesOther tracked companies whose held documents mention Biolife Solutions Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“…Exhibit 99.3 Repligen Employee FAQ 1. Why is Repligen acquiring BioLife Solutions? The acquisition is a natural next step in the evolution of our strategy and further strengthens our position as a leading… … comment on t”
“h Excited to announce another key milestone in our company's journey … the acquisition of BioLife Solutions BioLife Acquisition Will Build on Our Momentum Organic revenue growth is a non-GAAP… … Assumed limited sales synergies … cross sell/APAC Poten”
See also the earnings calendar for every tracked company’s next earnings date.